Associations - EGFR L861Q

BIOMARKER:

EGFR L861Q

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

EGFR L861Q EGFR L861Q	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR L861Q EGFR L861Q	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR L861Q EGFR L861Q	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B
EGFR L861Q EGFR L861Q	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR L861Q EGFR L861Q	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C2 – Inclusion Criteria osimertinib Sensitive : C2
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
EGFR L861Q EGFR L861Q	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
EGFR L861Q EGFR L861Q	Lung Cancer Lung Cancer	pan-ErbB inhibitor Sensitive: D – Preclinical pan-ErbB inhibitor Sensitive : D
EGFR L861Q EGFR L861Q	Esophageal Cancer Esophageal Cancer	erlotinib Resistant: D – Preclinical erlotinib Resistant : D
EGFR L861Q EGFR L861Q	Esophageal Cancer Esophageal Cancer	cetuximab Resistant: D – Preclinical cetuximab Resistant : D
EGFR L861Q EGFR L861Q	Esophageal Cancer Esophageal Cancer	afatinib Sensitive: D – Preclinical afatinib Sensitive : D